Project

Biological cancer therapy -Di Bella Method

Updates
0 new
0
Recommendations
0 new
0
Followers
0 new
3
Reads
0 new
114

Project log

Giuseppe Di Bella
added 2 research items
BACKGROUND & HYPOTHESIS: Overall evaluation and ongoing statistical processing of preliminary data on 502 evaluable cases of breast cancer on 11,300 patients who have been treated with DBM since 2004. METHODS: Administration of DBM to patients with breast cancer: somatostatin / octreotide, estrogenic and prolactin inhibitors, Melatonin, Retinoid solution in vitamin E, Vitamin D3, vitamin C, chondroitin sulfate, glucosamine and metronomic doses of cyclophosphamide. In breast tumors, given the GH receptor co-expression with prolactin and functional co-expression with estrogen, synergistic inhibition of GH and related growth factors with somatostatin/octreotide is indicated; inhibition of prolactin through D2R agonists and estrogen inhibition through FSH-LH analogues and aromatase inhibitors with negative regulation of proliferation, migration and neoplastic angiogenesis. RESULTS: If applied early and with absolute regularity as an exclusive first-line therapy, after seven years the DBM has made it possible to reduce relapses to below 1%. A 5-year survival of 69% was obtained in 297 cases at the IV stage [2]. The first of these cases, under treatment for 15 years, is still in remission of the disease [3-5]. The results obtained in the 441 cases published in previous publications [1-2-3-4] relating to the objective response, survival, quality of life and tolerability of DBM, are consistent and are fully confirmed in the hundreds of cases still under observation. CONCLUSION: In the absence of toxicity, DBM significantly improved quality of life, objective response and survival compared to the same stages of breast cancers treated with conventional cancer protocols. It is clear that the multitherapy synergism of DBM, unlike the high toxicity and reduced efficacy of cytoxic therapies, pursues the restoration of physio-biological functions and inhibits neoplastic proliferation.
Complete and stable objective response of 12 prostate cancer patients who were neither operated nor chemo-radiotreated but treated only with Di Bella Method (DBM) as first-line therapy. OBJECTIVE: To evaluate the objective clinical, biochimical and metabolical response and the safety of the combined administration of Di Bella Method (DBM) in patients with a histological diagnosis of prostate adenocarcinoma. MATERIALS AND METHODS: Twelve patients with a certain diagnosis of prostate cancer and with measurable disease characteristics were evaluated according to the RECIST criteria. The 12 patients had not been previously operated on or chemo-radiotreated. After giving informed consent, they voluntarily accepted the administration of the treatment as first-line therapy. In detail, they were administered in the following ways: • All-trans retinoic acid solution (ATRA, 1543488.372 IU), axerophthol palmitate (909000 IU), beta-carotene (3334000 IU) in alpha tocopheryl acetate (1000000 IU), in a stoichiometric ratio of 1: 1: 4: 2; 2-3 in conjunction with • Dihydrotachisterol (cholecalciferol-Vit.D3, ATITEN ©; 15200 IU); • Somatostatin: scalar administration; • Tetracosactide (Synachten®-synthesis ACTH) with frequent monitoring of blood pressure and blood sugar; • Octreotide LAR (slow release) 30 mg intramuscular; • Enantone 3.75mg intramuscolar; • Bicatulamide (Casodex®) 50 mg; • Melatonin 5 mg; • Cabergoline 0.25 mg; • Bromocriptina® 2.5 mg; • Cyclophosphamide® (from 50 mg to 75mg) gradual dosage; • Ascorbic acid (Vit C) gradual dosage, with • Carbonate calcium 500 mg in the same glass; • Chondroitin sulfate 250 mg + Glucosamine 250 mg; • Sideral; • Calciolevofolinate 22 mg RESULTS AND CONCLUSIONS: This preliminary study shows that all 12 patients not previously treated by surgery and/or chemo-radiotherapy, can achieve a more than positive clinical benefit and they alla achieved a five-year stable objective clinical instrumental, metabolic, biochemical complete remission with DBM applied as first-line therapy. Further clinical inestigations are recommended.
Giuseppe Di Bella
added a research item
Abstract Background: The interaction between pituitary hormones (Growth Hormone-Prolactin), ovarian hormones (Estradiol) and growth factors forms the basis of the mechanisms underlying the growth of tumors of the breast. The literature contains reports of the increased expression of the mitogenic GH (Growth Hormone)/IGF1 (Insulin-Like Growth Factor) axis in tumor tissues compared to healthy tissues, with a directly proportional dose-dependent relationship between GH/IGF1, proliferative index and invasive ability in numerous types of tumors. Methods and Findings: We carried out this experimental research on the mitogenic role of GH and consequently on the rationale of the anticancer use of its inhibition. The levels of expression of several genes, GH and GHR, were evaluated in 39 cases of breast cancer, divided according to different risk levels on the basis of immunohistochemical and histological tests with nuclear grade. Conclusion: Research showed that breast cancers with a high and intermediate risk of recurrence are characterized by over-expression of GH and of its receptor (GHR). The expression was limited in cases with a low risk. The overexpression of GH-GHR in breast cancer with a ratio proportional to the level of aggressiveness is a rationale that can encourage a therapeutic intervention with inhibition of the mitogenic GH-IGF1-PRL axis and estrogen. Keywords: Growth hormone; Somatostatine; Breast cancer; Mitogenic axis; Growth factor